PT  - JOURNAL ARTICLE
AU  - Gisby, Jack
AU  - Clarke, Candice L.
AU  - Medjeral-Thomas, Nicholas
AU  - Malik, Talat H.
AU  - Papadaki, Artemis
AU  - Mortimer, Paige M.
AU  - Buang, Norzawani B.
AU  - Lewis, Shanice
AU  - Pereira, Marie
AU  - Toulza, Frederic
AU  - Fagnano, Ester
AU  - Mawhin, Marie-Anne
AU  - Dutton, Emma E.
AU  - Tapeng, Lunnathaya
AU  - Richard, Arianne C.
AU  - Kirk, Paul D. W.
AU  - Behmoaras, Jacques
AU  - Sandhu, Eleanor
AU  - McAdoo, Stephen P.
AU  - Prendecki, Maria F.
AU  - Pickering, Matthew C.
AU  - Botto, Marina
AU  - Willicombe, Michelle
AU  - Thomas, David C.
AU  - Peters, James E.
TI  - Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and predictors of death
AID  - 10.1101/2020.11.05.20223289
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.11.05.20223289
4099  - http://medrxiv.org/content/early/2021/02/15/2020.11.05.20223289.short
4100  - http://medrxiv.org/content/early/2021/02/15/2020.11.05.20223289.full
AB  - End-stage kidney disease (ESKD) patients are at high risk of severe COVID-19. We measured 436 circulating proteins in serial blood samples from hospitalised and non-hospitalised ESKD patients with COVID-19 (n=256 samples from 55 patients). Comparison to 51 non-infected patients revealed 221 differentially expressed proteins, with consistent results in a separate subcohort of 46 COVID-19 patients. 203 proteins were associated with clinical severity, including IL6, markers of monocyte recruitment (e.g. CCL2, CCL7), neutrophil activation (e.g. proteinase-3) and epithelial injury (e.g. KRT19). Machine learning identified predictors of severity including IL18BP, CTSD, GDF15, and KRT19. Survival analysis with joint models revealed 69 predictors of death. Longitudinal modelling with linear mixed models uncovered 32 proteins displaying different temporal profiles in severe versus non-severe disease, including integrins and adhesion molecules. These data implicate epithelial damage, innate immune activation, and leucocyte-endothelial interactions in the pathology of severe COVID-19 and provide a resource for identifying drug targets.Competing Interest StatementNone of the authors have any patents (planned, pending or issued) relevant to this work. Dr. McAdoo reports personal fees from Celltrion, Rigel, GSK and Cello, unrelated to the submitted work. Dr Peters has received travel and accommodation expenses and hospitality from Olink to speak at Olink-sponsored academic meetings (>36 months ago). None of the other authors have any competing interests.Funding StatementThis research was partly funded by Community Jameel and the Imperial President's Excellence Fund and by a UKRI-DHSC COVID-19 Rapid Response Rolling Call (MR/V027638/1) (to JEP). We also acknowledge a contribution from UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC) and the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. JEP is supported by UKRI Innovation Fellowship at Health Data Research UK (MR/S004068/2). DCT is supported by a Stage 2 Wellcome-Beit Prize Clinical Research Career Development Fellowship (20661206617/A/17/Z and 206617/A/17/A) and the Sidharth Burman endowment. MCP is a Wellcome Trust Senior Fellow in Clinical Science (212252/Z/18/Z). NM-T and ES are supported by Wellcome Trust and Imperial College London Research Fellowships, and CLC by an Auchi Clinical Research Fellowship. PDWK is supported by the UK Medical Research Council (MC_UU_00002/13).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study ethics were reviewed by the UK National Health Service (NHS) Health Research Authority (HRA) and Health and Care Research Wales (HCRW) Research Ethics Committee (reference 20/WA/0123: The impact of COVID-19 on patients with renal disease and immunosuppressed patients). Ethical approval was given. All participants (patients and controls) were recruited from the Imperial College Renal and Transplant Centre and its satellite dialysis units, London, and provided written informed consent prior to participation.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFull summary statistics are included in the Supplementary File 1. Individual-level proteomic and clinical phenotyping data are available as Source Data Files. Code is available in the following GitHub repository: https://github.com/jackgisby/longitudinal_olink_proteomics